Similar articles

• Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.

  Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Farrell RJ, et al. Gastroenterology. 2003 Apr;124(4):917-24. doi: 10.1053/gast.2003.50145. Gastroenterology. 2003. PMID: 12671888 Clinical Trial.
• Immunogenicity of infliximab in Crohn's disease.

  Hanauer SB. Hanauer SB. N Engl J Med. 2003 May 22;348(21):2155-6; author reply 2155-6. doi: 10.1056/NEJM200305223482121. N Engl J Med. 2003. PMID: 12761378 No abstract available.
• Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.

  Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R; REACH Study Group. Hyams J, et al. Gastroenterology. 2007 Mar;132(3):863-73; quiz 1165-6. doi: 10.1053/j.gastro.2006.12.003. Epub 2006 Dec 3. Gastroenterology. 2007. PMID: 17324398 Clinical Trial.
• Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy.

  Lichtenstein GR. Lichtenstein GR. Am J Gastroenterol. 2005 Jul;100(7):1433-5. doi: 10.1111/j.1572-0241.2005.50622_1.x. Am J Gastroenterol. 2005. PMID: 15984959 Review. No abstract available.
• Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.

  Gisbert JP, Panés J. Gisbert JP, et al. Am J Gastroenterol. 2009 Mar;104(3):760-7. doi: 10.1038/ajg.2008.88. Epub 2009 Jan 27. Am J Gastroenterol. 2009. PMID: 19174781 Review.